FDA panel backs compounded BPC-157, KPV

On 23 July 2026 the US Food and Drug Administration's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention^[1], to recommend that compounding pharmacies be allowed to prepare two unapproved peptides. The panel backed BPC-157 for ulcerative colitis, and KPV for wound healing and inflammatory conditions^[1]. The recommendation would add both substances to the Section 503A Bulks List^[2], the roster of ingredients that pharmacies may lawfully compound into medicines. The committee only advises. The FDA makes the final decision and is not bound by the vote, though it usually follows its panels.

What the panel actually voted on

Compounding is the practice of a licensed pharmacy preparing a medicine to order, usually for a patient who cannot use a commercially available product. Section 503A of the Federal Food, Drug, and Cosmetic Act limits which bulk ingredients pharmacies may use for that purpose, and the 503A Bulks List is the approved roster^[2]. BPC-157 and KPV are not on it today. A yes vote from the committee is a recommendation to add them, not a finding that either peptide is safe, effective, or approved as a drug.

The distinction matters for anyone reading the headlines. Nothing in this vote grants BPC-157 or KPV a marketing authorisation, and neither peptide has been through the large trials the FDA requires before it approves a new drug. What the panel weighed was narrower: whether pharmacies should be permitted to compound these substances at all. The BPC-157 regulation section on our peptide page tracks where that question stands.

Why the vote counts as a win for peptide proponents

The result lands as a victory for the wellness and anti-aging clinics that have sold compounded peptides for years, and for health secretary Robert F. Kennedy Jr., who has publicly voiced support for wider peptide access^[1]. In June the FDA added new members to the committee, some with reported ties to peptide promotion, a change that drew criticism over potential conflicts of interest^[1].

The agency's own scientists did not share the enthusiasm. FDA reviewers recommended against adding the peptides, telling the committee that BPC-157 is not well characterised and that basic questions about its identity and quality remain open^[1]. One committee member from MD Anderson Cancer Center pointed to the absence of efficacy data and randomised controlled trials^[1].

What the evidence on BPC-157 shows

BPC-157, short for Body Protection Compound 157, is a 15-amino-acid synthetic peptide. Its reputation for healing tendons, ligaments and the gut rests almost entirely on studies in rats, mice and dogs. The US Department of Defense's Operation Supplement Safety programme states plainly that there is little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans, and that it is an unapproved drug that cannot be legally prescribed or sold over the counter^[3].

The same programme notes that the FDA has already warned against compounded drugs containing BPC-157, citing safety risks and possible contamination with other substances^[3]. That warning is part of what makes the committee's vote so striking: the agency's safety materials and its compounding advisors are now pointing in opposite directions. BPC-157 circulates, like other grey-market peptides such as TB-500, through 'research use only' vials with no pharmaceutical-grade quality control.

What the vote does not change

For now, nothing about the legal status of BPC-157 or KPV changes. Both peptides remain unapproved. Compounding eligibility, if the FDA grants it, would let pharmacies prepare the substances, but it would not make them approved medicines and it would not generate the human safety and efficacy data that neither peptide has. A separate new-drug process, far longer and more demanding, would be needed for that.

KPV, a short peptide studied for its anti-inflammatory effects, has an even thinner public evidence base than BPC-157, and the committee weighed it on the same day. The FDA is expected to issue its own determination on both peptides after reviewing the recommendation. Readers in the United States can follow the regulatory picture on our United States regulation hub and the BPC-157 regulation section.

Where this lands

A committee recommendation is a signal, not a finish line. If the FDA follows its advisors, compounded BPC-157 and KPV would move from an unauthorised grey market into a regulated compounding channel. That would change how the peptides are made and sold without changing how well they are proven to work. The gap between easier access and thin evidence is the part worth watching. Our United States regulation hub logs the status as the FDA decides. This article is educational and not medical advice. Anyone considering a peptide should talk to a clinician who knows their medical history.